Clinical Trial Update: Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis [Phase 3]

View source ↗

Summary

Phase 3 extension study for AIN457 in active non-infectious uveitis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveitis

Drugs mentioned

• AIN457

Snippet

Sponsor: Novartis | Conditions: Uveitis | Phase 3 | Status: WITHDRAWN